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IntroduCtIon
The spread of severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2) has be-
come a rapidly devastating global pandemic. 
Veno-venous extracorporeal membrane oxy-
genation (V-V ECMO) may be a highly effective 
and lifesaving therapy for acute refractory res-
piratory failure (ARRF) in the context of acute 
respiratory compromise such as that induced by 
SARS-CoV-2. Recent studies indicate that there 
is a 35%–50% mortality rate for critically ill pa-
tients. However, since the increased prevalence 
of the British variant strain of COVID-19, patient 
mortality while on extracorporeal circulation 
has increased dramatically. This is despite the 
growing medical experience with COVID-ECMO, 
previous ECMO therapies, patient selection, 
and the objectively lower number of serious 
complications caused by therapy [1]. The study 
aims to outline the differences between COV-
ID-ECMO during the first and next waves of the 
pandemic, with a particular interest in mortality, 
patient characteristics, and referral destination. 
The current study was not subjected to review 
by a bioethical committee. The data are anon-
ymous, retrospectively collected, and derived 
from a single-center registry. 
Having predicted the necessity to support 
patients critically ill with COVID-19 ARRF with 
V-V ECMO, and in order to make optimal use 
of the expertise and resources of the Clinical 
Department of Cardiac Surgery (Central Clinical 
Hospital of the Ministry of Interior and Admin-
istration), this study founded The Centre for 
Extracorporeal Therapies (CET) at the beginning 
of the pandemic, on March 20th, 2020. The CET 
has since been serving as a subunit of the 
Clinical Department of Cardiac Surgery, using 
the expertise of cardiac anesthetists, cardiac 
surgeons, cardiologists, perfusionists, and 
intensivists and admitting patients from the 
entire voivodeship and beyond. Recently, due 
to the growing number of patients requiring 
extracorporeal therapy, the CET has expanded 
and now includes the general Department of 
Anesthesiology and Intensive Care (Central 
Clinical Hospital of the Ministry of Interior 
and Administration).
The CET team also established the mo-
bile-ECMO team for patients experiencing 
mobility barriers. This team involving an an-
esthetist, cardiac surgeon, and perfusionist to 
ensure complications can be safely addressed 
while en-route to the CET. In close cooperation 
with the Polish Medical Air Rescue service and 
Emergency Medical Services (EMS), this study 
also established dispatch and transport proce-
dures for ECMO-dependent patients.
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Methods
The registry included all 75 consecutive cases of COV-
ID-ECMOs admitted to our department between March 
20th, 2020 to March 20th, 2021. Patients were candidates 
for ECMO therapy if they tested positive for COVID-19 or 
displayed a history of having contracted COVID-19. Patients 
also had to have met the criteria for ECMO support in ARRF 
as described by the Board of Intensive Care document and 
adopted by the Agency for Health Technology Assessment 
and Tariff System (AOTMIT) [2]. This study was approved 
by the Institutional Review Board but patient consent 
for inclusion in the registry was waived. Transesophageal 
echocardiography (TEE) was performed to assess ventricu-
lar function and determine the positioning of the ECMO 
cannulas. All patients underwent computed tomography 
to determine the extent of pulmonary involvement. When 
a transition to veno-arterial (V-A) ECMO was necessary, the 
ECMO heart team would meet this identified need.
Early mortality was defined as mortality (of any cause) 
during the index hospitalization or within 30 days of admis-
sion. Complications were identified through the application 
of institutional protocols and definitions. 
This study examined patients that were treated in 
the first wave (March 20th 2020–July 30th 2020) vs the 
next waves (August 1st 2020–March 20th 2021) as per 
epidemic Renormalisation Group temporal definition [3]. 
Mean ± standard deviations (SD) were used for normally 
distributed variables, while for non-normal distributions 
median and interquartile range (IQR) were used and com-
pared with the Mann–Whitney U test or standard t test as 
appropriate. A two-tailed P-value of <0.05 was considered 
significant. STATA MP 13.0 (StataCorp, College Station, TX) 
was used for data analyses.
results and dIsCussIon
Seventy-five patients (15 [20.0%] women) underwent 
ECMO therapy to address COVID-19 symptoms; 16 (21.3%) 
were treated between March 20th, 2020 and July 30th 
2020 and the remaining 59 (78.7%) were treated between 
August 1st, 2020 and March 20th, 2021. The prevalence of 
ARRF was the primary consideration for the application of 
ECMO therapy for all patients. Concomitant symptoms con-
sidered for the application of V-V ECMO therapy included 
sepsis (1 case), massive pulmonary embolism (1 case) and 
pulmonary PISZEMY AmEng edema (1 case). One patient 
presented with malignant ventricular arrhythmia and 
V-A ECMO. In 23 patients (30.6%), ECMO was applied off-
site and patients were later transferred to the CET Warsaw 
location. Eight patients reached CET by air (Figure 1). 
The mean age of patients treated before August 1st, 
2020 was 53.6 years (SD 9.3) and was significantly higher 
than this of patients treated after August 1st, 2020 (46.8 [SD 
8.5]); P = 0.007). The median duration from ventilator use to 
ECMO therapy was 7 (IQR [3–9]) days in the first temporal 
group vs 5 days (IQR [2–7]) in the second temporal group. 
However, this difference was not significant. The mean 
duration of ECMO therapy was 11 days (SD 6.8) in the first 
temporal group and 18 days (SD, 7.3) in the second (P 
<0.001). Ten patients (62.5%) were successfully weaned 
and survived to discharge in the first temporal group. As 
of March 29th, 2021, 40 patients died in the second group; 
of those, 3 after having been weaned from support, trans-
lating into 40.7 % weaning and 32.2% survival rates respec-
tively. Twelve ECMOs are currently operating (10 Cardiohelp 
[Maquet Cardiovascular, Bridgewater, NJ], 1 RotaFlow 
[Maquet Cardiovascular, Bridgewater, NJ], 1 LivaNova ECC 
[LivaNova PLC, London, UK] in ECMO setup) (Supplemen-
tary material, Video S1). Eight patients were listed for lung 
transplantation; of those, 4 patients received referrals to 
a lung transplant center and 4 underwent successful lung 
transplantation. 
Our preliminary data suggest that patients with se-
vere refractory respiratory or cardiac failure due to COV-
ID-19 and who were placed on ECMO therapy had a rea-
sonable (62.5%) chance of survival during the first wave of 
the COVID-19 pandemic. The majority of these individuals 
could have been successfully discharged from ECMO ther-
apy. During the first wave of therapy, we introduced the 
mobile COVID-ECMO therapy resource, which continues to 
be among the most active in Poland, able to apply ECMO 
therapy off-site and transport patients to the extracor-
poreal therapy hub. Air medical services provided by the 
Polish Medical Air Rescue — and by police and military air 
forces — supported logistics and patient transfer to and 
from remote site locations and, more recently, supported 
the transfer of patients to lung-transplant referral centers. 
It is significant to note that this study was the first to 
introduce an ECMO-heart team, a team of professionals in-
cluding a cardiac surgeon, perfusionist, cardiac anesthetist, 
cardiologist, and intensivists together with the supportive 
work of an intensive-care and anesthetist nurse. The cardiol-
ogist was a highly valuable addition to the team for various 
reasons. Peripheral V-V ECMO takes over the pulmonary 
function of blood oxygenation; by doing so, blood SO2 is 
no longer representative of deteriorating heart conditions 
and RV failure. Routine echocardiographic check-ups help to 
determine the optimal time to upgrade the V-V ECMO circuit 
to more advanced configurations, such as V-VV, V-VA, VA-V, 
or V-VVA. This transition is needed in order to better address 
a failing RV, avoid differential hypoxia, and  react to a patient’s 
rapidly changing health conditions. In addition, optimal 
anticoagulation poses a major challenge for COVID-19 pa-
tients undergoing ECMO therapy, due to increased risk of 
thrombosis, bleeding, and other coagulation disorders [4].
A recent report from the Extracorporeal Life Support 
Organization (ELSO) Registry aimed to characterize the epi-
demiology, hospital course, and outcomes of patients aged 
16 years or older with confirmed cases of COVID-19 and 
who underwent ECMO therapy between January 16th, and 
May 1st, 2020 at 213 hospitals in 36 countries. The report 
found that the estimated mortality of patients 90 days 
after undergoing ECMO therapy was less than 40% [1], 
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aligning with the results of this study regarding the first 
wave. More recently, the ELSO survey presented less 
encouraging results. A trend toward increased mortality 
has been observed across European countries and also 
reported in a systematic review which found mortality rate 
in adult patients with COVID-19 on ECMO of about 75% [5] 
attributable, in part, to novel strains of COVID-19 leading 
to higher infection rates, more severe manifestations 
and more COVID-19 hospitalizations and deaths among 
younger individuals. Additional data analysis is needed 
to provide information on the demographics, severity of 
illness, symptoms, and different ECMO therapy manage-
ment strategies in these patients.
ConClusIons
ECMO is a valuable tool in the treatment of COVID-19 pa-
tients presenting with acute respiratory insufficiency refrac-
tory to other supportive measures. The trends are chang-
ing, however, with regards to patient profile, destination 
therapy and predicted mortality, with younger patients 
being admitted, higher observed mortality and the in-
creasing number of candidates for lung transplantation 
as destination therapy. COVID-19 pandemic required that 
ECMO-patient transport procedures are formally and prac-
tically implemented. Done so, we believe these may serve 
critically ill patients in the future.
Supplementary material
Supplementary material is available at https://journals.
viamedica.pl/kardiologia_polska.
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Figure 1. Air medical transport of ECMO patient
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